| Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei |
2013-001445-13: Assessment of the early bronchodilation of Glycopyrronium bromide compared to Tiotropium in patients with moderate to severe COPD |
|
|
| Not yet recruiting | 4 | 150 | Europe | Glycopyrronium bromide, Spiriva Handihaler, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler, Spiriva Handihaler | Novartis Pharma GmbH, Novartis Pharma GmbH | Chronic Obstructive Pulmonary Disease (COPD), COPD is a chronic condition of the lungs which causes people to suffer symptoms such as shortness of breath and coughing., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-004972-32: Pharmacokinetics, pharmacodynamics, safety and tolerability of glycopyrronium (bromide) in children (6 to less than 12 years) with asthma. Farmacocinética, farmacodinámica, seguridad y tolerabilidad de bromuro de glicopirronio en niños con asma (de 6 a menos de 12 años de edad). |
|
|
| Ongoing | 2 | 42 | Europe, RoW | Glycopyrronium bromide 25 μg of active moiety in the capsule, Glycopyrronium bromide 12.5 μg of active moiety in the capsule, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler | Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG | Asthma Asma, Asthma Asma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05222529 / 2021-004972-32: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma |
|
|
| Recruiting | 2 | 42 | Europe, RoW | Glycopyrronium bromide 25ug, NVA237, Placebo, Glycopyrronium bromide 12.5ug | Novartis Pharmaceuticals, Novartis Pharma AG | Asthma | 06/25 | 06/25 | | |
| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi |
| Not yet recruiting | 4 | 70 | Europe | Flutiform K-haler, Relvar Ellipta, Inhalation solution, Inhalation powder, Flutiform K-haler, Relvar Ellipta | HUS / Mika Mäkelä, Mika Mäkelä | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ChiCTR1800019111: An open-label, single-dose and single- plus multiple-dose study to assess the pharmacokinetic profile of FLUTIFORM pMDI 50/5 μg (100/10 μg total dose), 125/5 μg (250/10 μg total dose), and 250/10 μg (500/20 μg total dose) in healthy Chinese subjects |
|
|
| Recruiting | 1 | 36 | | FLUTIFORM pMDI single-dose administration (50/5 μg, 125/5 μg, and 250/10 μg) and multiple-dose administration (250/10 μg) | West China Hospital, Sichuan University; Mundipharma (China) Pharmaceutical Co. Ltd, Mundipharma (China) Pharmaceutical Co. Ltd | Asthma | | | | |
| Triglide (fenofibrate) / Vectura, Shionogi |
NCT06191133: Fenofibrate in Patients with Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma |
|
|
| Not yet recruiting | 1 | 24 | NA | Fenofibrate, Antara, Fenoglide, Lipofen, Tricor, Triglide, Cervical Conization, Hysterectomy, Chemoradiation | Lindsay Ferguson, MD | Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer | 06/26 | 11/26 | | |
| apomorphine inhalational (VR 040) / Vectura, Kyowa Kirin |
2006-004582-33: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing Off” Episodes in Patients With Advanced Idiopathic Parkinson’s Disease |
|
|
| Ongoing | 2 | 24 | Europe | Apomorphine hydrochloride, VR040, | Vectura Group plc | Hypomobility (off or freezing) episodes associated with advanced Parkinson\'s disease | | | | |
| heparin sodium (VR496) / Vectura |
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV |
|
|
| Active, not recruiting | 2 | 60 | US | VRX496-Modified Autologous T cells | VIRxSYS Corporation | HIV Infection | 11/08 | 06/23 | | |
| Active, not recruiting | 2 | 40 | US | VRX496-transduced autologous CD4 T cells | VIRxSYS Corporation | HIV Infections | 01/09 | 06/23 | | |
| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis |
2019-001762-14: Anti-inflammatory effects of Glycopyrronium Ontstekingsremmend effect Glycopyrronium |
|
|
| Not yet recruiting | 3 | 28 | Europe | QMF149, QVM149, Inhalation powder | University Medical Center Groningen, Novartis Pharma AG | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
NCT05776927: A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. |
|
|
| Not yet recruiting | 3 | 304 | NA | QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149, Placebo to Salmeterol Xinafoate / Fluticasone Propionate, Run-In Medication, Rescue Medication, Concept 1 Device, Girohaler | Novartis Pharmaceuticals | Asthma | 03/26 | 08/27 | | |
| Completed | N/A | 434 | Europe | MF/IND/GLY plus sensor system, FDC therapy | Novartis Pharmaceuticals | Asthma | 01/23 | 01/23 | | |
ChiCTR2300079273: Effect of Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose triple formulation on pulmonary function, symptoms and inflammation control in patients with asthma complicated with COPD |
|
|
| Not yet recruiting | N/A | 96 | | Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose (160/150/50μg,qd); Budesonide formoterol inhalation powder aerosol (160/4.5 micrograms, 2 inhalations per bid) plus tiotropium bromide inhaler (2.5 micrograms, once a day, 2 inhalations per inhalation); Budesonide, Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol (160/4.8/7.2μg,bid,2 inhalations per inhalation) | Lishui People's Hospital; LiShui people's hospital, China Medical Foundation | asthma-COPD overlap | | | | |
NCT05274425: A 24-week rPMS Study in Real-world Setting for Enerzair |
|
|
| Recruiting | N/A | 600 | RoW | Enerzair 150/50/80 μg, Enerzair 150/50/160 μg | Novartis Pharmaceuticals | Asthma | 12/26 | 12/26 | | |
| frevecitinib (KN-002) / Vectura, Kinaset Therap |
| Completed | 1 | 117 | Europe | KN-002 | Kinaset Therapeutics Inc | Asthma COPD | 12/23 | 07/24 | | |
| budesonide inhalation (VR647) / Vectura |
| No trials found |
| VR2081 / Vectura, Novartis |
| No trials found |
| VR506 / Hikma, Vectura |
| No trials found |
| imatinib (AER-901) / Aerami Therap |
| No trials found |
